Home Journals Articles Updates About
CN
image
收藏切换
Analysis of RNA modifications in peripheral white blood cells from breast cancer patients by mass spectrometry
收藏切换
PDF
Keqiang Shia, b, c, Xiujuan Honga, c, Dongyan Xua, c, Tao Pand, Huiwen Wange, Hongru Fengb, Cheng Guoa, c, *, Yuanjiang Panb, *
Chinese Chemical Letters | 2025, 36(3) : 110079
Less
收藏切换
Chinese Chemical Letters | 2025, 36(3): 110079
• Communication •
Analysis of RNA modifications in peripheral white blood cells from breast cancer patients by mass spectrometry
Full
Keqiang Shia, b, c, Xiujuan Honga, c, Dongyan Xua, c, Tao Pand, Huiwen Wange, Hongru Fengb, Cheng Guoa, c, *, Yuanjiang Panb, *
Affiliations
  • a Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
  • b Department of Chemistry, Zhejiang University, Hangzhou 310058, China
  • c Cancer Center, Zhejiang University, Hangzhou 310058, China
  • d Department of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
  • e Analysis Center of Agrobiology and Environmental Sciences, Zhejiang University, Hangzhou 310058, China
Published: 2025-03-15 doi: 10.1016/j.cclet.2024.110079
Outline
收藏切换

RNA modifications play vital regulatory roles in biological systems. Dysregulated RNA modifications themselves or their regulators are associated with various diseases, including cancers and immune related diseases. However, to the best of our knowledge, RNA modifications in peripheral white blood cells (immune cells) have not been systematically investigated before. Here we utilized hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC-MS/MS) for the quantification of 19 chemical modifications in total RNA and 17 chemical modifications in small RNA in peripheral white blood cells from breast cancer patients and healthy controls. We found out 13 RNA modifications were up-regulated in total RNA samples of breast cancer patients. For small RNA samples, only N6-methyladenosine (m6A) was down-regulated in breast cancer patients (P < 0.0001). Receiver operating characteristic (ROC) curves analysis showed that N4-acetylcytidine (ac4C) in total RNA had an area under curve (AUC) value of 0.833, and m6A in small RNA had an AUC value of 0.994. Our results further illustrated that RNA modifications may play vital roles in immune cell biology of breast cancer, and may act as novel biomarkers for the diagnosis of breast cancer.

RNA modification  /  Mass spectrometry  /  Breast cancer  /  Immune cell  /  Biomarker
Keqiang Shi, Xiujuan Hong, Dongyan Xu, Tao Pan, Huiwen Wang, Hongru Feng, Cheng Guo, Yuanjiang Pan. Analysis of RNA modifications in peripheral white blood cells from breast cancer patients by mass spectrometry[J]. Chinese Chemical Letters, 2025 , 36 (3) : 110079 - . DOI: 10.1016/j.cclet.2024.110079
Full Text
Less
Beyond the classical central dogma of molecular biology, DNA modifications, RNA modifications and protein post-transcriptional modifications play vital roles in biological systems [1]. More than 170 RNA modifications have been reported [2,3], and novel RNA modifications are discovered almost every year [4–6]. Especially, small RNAs (<200 nt, mainly tRNAs) are considered heavily modified [7–9], and these modifications are related to the diagnosis and treatment of human diseases [10]. Increasing evidence illustrates that the levels of RNA modifications themselves or related proteins (writers, readers and erasers) are dysregulated in various diseases, especially cancers [11–16].
Blood can be separated into different fractions, for example, serum or plasma, platelets or circulating tumor cells (CTCs), in order to enrich for tumor biomarkers [17]. Mass spectrometry is a powerful tool for the identification and quantification of RNA modifications [18,19]. Numerous studies have been conducted on free modified nucleosides in the serum or plasma from patients with different cancer types [20]. RNA modifications in blood have also been shown to be related to various physiological or pathological processes, for example, aging [21], adolescent alcohol exposure [22], smoking and air pollution [23], colorectal cancer [24,25] and pulmonary hypertension [26]. RNA modifications in CTCs of lung cancer patients have also been investigated [27].
However, to the best of our knowledge, RNA modifications in peripheral white blood cells of breast cancer patients have not been systematically investigated before. Considering white blood cells are parts of the immune system, and RNA modifications are involved in immune cell biology and cancer immunity [28–30], it is important and desirable to investigate RNA modifications in peripheral white blood cells.
In this work, we aimed to study RNA modifications in total RNA and small RNA in peripheral white blood cells from breast cancer patients. As shown in Fig. 1, total RNA was extracted using Trizol reagent, and small RNA was extracted using a commercially available kit. The purities of RNA samples were verified by agarose gel electrophoresis. Total RNA and small RNA samples were enzymatically digested into ribonucleosides. Then, hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC-MS/MS) was used for the quantification of these RNA modifications.
Firstly, we used Trizol reagent for extraction of total RNA from whole blood cells. However, we found out RNA was degraded and DNA was mainly obtained from blood samples whether frozen at −80 ℃ or freshly collected (Fig. S1 in Supporting information). This might be attributed to the presence of abundant RNases in red blood cells [31]. With the help of red blood lysis, we could remove red blood cells before RNA extraction. And high purity RNA samples were obtained based on non-denaturing agarose gel electrophoresis (Fig. S2 in Supporting information). Small RNA samples were isolated by a commercially available kit, the extraction process was repeated once in order to guarantee their purity, and the purities of small RNA samples were also evaluated by non-denaturing agarose gel electrophoresis (Fig. S2). Detailed protocols for the isolation of total RNA and small RNA were shown in Supporting information.
For enzymatic digestion, about 1 µg of total RNA or 500 ng of small RNA samples were digested into ribonucleosides with the help of nuclease P1, phosphodiesterase 2 and antarctic phosphatase, and detailed protocols were shown in the Supporting information [32]. HILIC-MS/MS was used for the detection and quantification of these RNA modifications based on Acquity UPLC system and QTRAP 4000 mass spectrometer. Optimized mobile phase elution gradient and MRM parameters were shown in materials and methods section and Table S1 (Supporting information) [33–35].
The chemical structures and detailed information of RNA modifications and their isotope-labeled internal standards tested in this study were shown in Fig. S3, Fig. S4 and Table S2 (Supporting information), respectively. Compared with retention time of their isotope-labeled standards (for Am, m1A, m6A, m26A, Gm, m1G, m7G, m2,2G, Cm, m5C, ac4C, Um, m3U, m5U and ψ) or standards (for m6Am, m2G, m3C and m5Um), we could detect 19 RNA modifications in total RNA samples (Am, m1A, m6A, m6Am, m26A, Gm, m1G, m2G, m7G, m2,2G, Cm, m3C, m5C, ac4C, Um, m3U, m5U, m5Um and ψ), and 18 RNA modifications in small RNA samples (except m6Am, compared with modifications in total RNA) (Fig. 2). In order to exclude the contamination from enzymes, enzyme blank experiments were carried out and the results indicated these RNA modifications were not detected in the enzyme blank samples (Fig. S5 in Supporting information).
To realize accurate quantitative analysis, calibration curves of canonical ribonucleosides (adenosine (A), guanosine (G), cytidine (C) and uridine (U)) and these RNA modifications were built by serial dilution of standards and addition of isotope-labeled internal standards (detailed methods in Supporting information). For those without isotope-labeled standards, [D3]Am, [D6]m2,2G, [13CD3]m5C and [D3]Um were used as internal standards for the quantification of m6Am, m2G, m3C and m5Um, respectively. Calibration curves had excellent linearities, with R2 values larger than 0.998 (Table S3 in Supporting information). Limits of detection (LODs) and limits of quantification (LOQs) were in the range of 0.02–40 nmol/L and 0.05–80 nmol/L (Table S3), based on signal-to-noise ratio (S/N) of 3 and 10, respectively. In order to validate the developed method, accuracy and precision were tested. The intra-day accuracy values ranged from 81.0% to 112.9%, and the intra-day precision, as reflected by relative standard deviation (RSD), was within 8.6%. The inter-day accuracy values ranged from 80.7% to 112.6%, and the inter-day precision was within 11.8% (Table S4 in Supporting information).
Blood samples were obtained from the Second Affiliated Hospital, Zhejiang University School of Medicine (SAHZU). An approval was granted by the Medical Ethics Committee of SAHZU and subjects signed an informed consent form. We obtained total RNA samples from the white blood cells of 42 breast cancer patients and 43 healthy controls, and small RNA samples from 17 breast cancer patients and 20 healthy controls. Blood samples from breast cancer patients were obtained before surgery and without radiation or chemotherapy. Details of these samples were shown in Tables S5 and S6 (Supporting information). By using the established and validated method, we quantified RNA modifications in these samples.
As for total RNA in peripheral white blood cells, most of the quantified RNA modifications were up-regulated in breast cancer patients compared with healthy controls (Fig. 3). The statistical analysis revealed that among these RNA modifications, m6Am, m1G, m2,2G, m5C, and ac4C had P values less than 0.0001; m5Um had P values less than 0.001; m2G, Cm and m5U had P values less than 0.01; m6A, m26A, Gm and m3C had P values less than 0.05.
As for small RNA in peripheral white blood cells, only m6A was down-regulated in small RNA samples from breast cancer patients (P < 0.0001), and other modifications in small RNA had no significant difference between breast cancer patients and healthy controls (Fig. 4).
In addition, we found small RNA samples had relatively higher levels of m1A, m6A, m3C, m5C, ac4C, m1G, m2G, m7G, m2,2G, m5U, m5Um and Ψ, lower levels of Am and m26A, and undetectable level of m6Am, compared with total RNA (Figs. 3 and 4 and Table S7 in Supporting information). These results were consistent with previously reported relative levels of these modifications in small RNA or tRNA, compared with their levels in total RNA [36–39], which further confirmed the purity of the small RNA samples we extracted.
We further performed receiver operating characteristic (ROC) curves analysis. It is interesting that ac4C in total RNA had an area under curve (AUC) value of 0.833, and m6A in small RNA had an AUC value of 0.994 (Fig. 5). AUC values of other significantly changed modifications in total RNA were shown in Fig. S6 (Supporting information). The combination of a panel of significantly changed modifications in total RNA (m6A + m26A + Gm + m1G + m2G + m2,2G + Cm + m5C + ac4C) had an AUC value of 0.892 (Fig. 5). m6Am, m5Um, m3C and m5U were excluded from total RNA diagnostic panel because they couldnot be quantified in all total RNA samples (Fig. 3).
We clarified 42 breast cancer patients into 27 early stage breast cancer (grades 0 and Ⅰ) and 15 locally advanced breast cancer (groups Ⅱ and Ⅲ) [40], and compared total RNA modification levels in the two groups. Only ac4C had significant differences between the two groups (P < 0.01), based on the Mann-Whitney test. Locally advanced breast cancer patients had lower levels of ac4C, compared with early stage breast cancer. Based on One-way ANOVA analysis, ac4C may act as a biomarker for early stage breast cancer (Fig. S7 in Supporting information).
These discoveries facilitated us to think about RNA modifications in immune cells and cancer biology. Although the roles of RNA modifications in breast cancer immunity are not well understood, various modifications such as m1A, m6A, m5C, ac4C, m7G and Ψ have been reported to play diverse roles in different aspects of immune cell biology [28]. As the most extensively investigated RNA modification [13,41], m6A has been shown to play vital roles in tumor immune microenvironment (TIME) and cancer progression [41,42]. For example, loss of function of METTL3 (a writer protein for the formation of m6A) has been found to suppress colorectal cancer cell growth through inhibition of the accumulation of myeloid-derived suppressor cells [43]. Besides, m6A regulators play important roles in antitumor immune response [44]. In addition, ac4C has been reported existing in tRNA, rRNA and mRNA [45,46], and recent discoveries have found out ac4C could facilitate cervical cancer progression and immunosuppression [47]. Synthetic mRNA with ac4C modification has been shown to be less inflammatory to immune cells than cytidine [48]. m5C has also been shown to play important roles in TIME, and related regulators may be valuable as biomarkers for the diagnosis and prognosis of cancers [49]. m6Am is part of cap structure in eukaryotic mRNA, and it is important in the immunorecognition of self and non-self [50]. m5Um in tRNA has been reported to decrease immune response [51]. Furthermore, m1A, m5C, ac4C, m7G and Ψ are found to be related to immune cell infiltration in cancers [41]. RNA with modifications like m5C, m6A, m5U, 2-thiouridine (s2U) and Ψ can help to get rid of organismic immune response [52]. Other significantly changed modifications in this study, such as m26A, Gm, m1G, m2G, m2,2G, Cm and m3C, may be less investigated in immune cell biology and cancer immunity, and future work need to be done to further understand their roles in these aspects.
As for future work, we should use a larger sample size to validate the ability of RNA modifications in peripheral white blood cells as biomarkers for detection of breast cancer. Besides, RNA modifications in white blood cells may be used for the differentiation of different subtypes or stages of breast cancer patients. Furthermore, the investigation of RNA modifications in different subtypes of immune cells (e.g., CD4+ T and CD8+ T lymphocytes, B lymphocytes, dendritic cells, monocytes or macrophages) is desirable and may benefit clinical practice [28,53]. In future studies, it would be also valuable to investigate RNA modifications in other types of blood RNA, such as poly(A)-tailed RNA (mainly mRNA), diverse rRNAs (5S, 5.8S, 18S and 28S rRNA) and small RNA (10–50 nt).
In conclusion, we extracted high quality total RNA and small RNA samples (confirmed by gel electrophoresis) in peripheral white blood cells from breast cancer patients and healthy controls. By using our established and validated HILIC-MS/MS method, we quantified 19 RNA modifications in total RNA samples and 17 RNA modifications in small RNA samples. 13 RNA modifications were found to be up-regulated in total RNA samples from breast cancer patients, especially for ac4C, with a P < 0.0001 and an AUC value of 0.833. As for small RNA, only m6A has significant difference between breast cancer patients and healthy controls, with a P < 0.0001 and an AUC value of 0.994. This work may contribute to not only the discovery of novel biomarkers based on RNA modifications in peripheral white blood cells, but also the deep understanding of RNA modifications in immune cell biology and cancer immunity.
Declaration of competing interest
Less
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
CRediT authorship contribution statement
Less
Keqiang Shi: Writing – original draft, Methodology, Investigation, Formal analysis, Data curation. Xiujuan Hong: Methodology, Investigation, Formal analysis, Data curation. Dongyan Xu: Resources. Tao Pan: Resources. Huiwen Wang: Writing – review & editing. Hongru Feng: Writing – review & editing. Cheng Guo: Writing – review & editing, Supervision, Funding acquisition. Yuanjiang Pan: Writing – review & editing, Supervision, Funding acquisition.
Acknowledgment
Less
This research was supported by National Natural Science Foundation of China (Nos. 21927810, 22336004 and 22176167).
Supplementary materials
Less
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2024.110079.
References
Less
[1]
T. Liu, C.J. Ma, B.F. Yuan, et al., Sci. China Chem. 61 (2018) 381–392.
[2]
P. Boccaletto, F. Stefaniak, A. Ray, et al., Nucleic. Acids. Res. 50 (2022) D231–D235.
[3]
P.J. McCown, A. Ruszkowska, C.N. Kunkler, et al., Wiley Interdiscip. Rev. RNA 11 (2020) 1–71.
[4]
X.J. You, S. Zhang, J.J. Chen, et al., Nucleic. Acids. Res. 50 (2022) 9858–9872.
[5]
T. Ohira, K. Minowa, K. Sugiyama, et al., Nature 605 (2022) 372–379.
[6]
Y.J. Feng, X.J. You, J.H. Ding, et al., Anal. Chem. 94 (2022) 4747–4755.
[7]
X. Zhang, A.E. Cozen, Y. Liu, et al., Trends Mol. Med. 22 (2016) 1025–1034.
[8]
X. Li, J. Peng, C. Yi, Non-Coding RNA Res. 6 (2021) 167–173.
[9]
J. Shi, T. Zhou, Q. Chen, Nat. Cell Biol. 24 (2022) 415–423.
[10]
Q. Xiong, Y. Zhang, J. Hematol. Oncol. 16 (2023) 64.
[11]
N. Jonkhout, J. Tran, M.A. Smith, et al., RNA 23 (2017) 1754–1769.
[12]
I. Barbieri, T. Kouzarides, Nat. Rev. Cancer 20 (2020) 303–322.
[13]
X. Han, M. Wang, Y.L. Zhao, et al., Semin. Cancer Biol. 75 (2021) 97–115.
[14]
Y. Matsumura, F.Y. Wei, J. Sakai, Nat. Metab. 5 (2023) 370–384.
[15]
I. Orsolic, A. Carrier, M. Esteller, Trends Genet. 39 (2023) 74–88.
[16]
Y. Liu, T. Zhu, Y. Jiang, et al., Front. Cell Dev. Biol. 10 (2022) 1–13.
[17]
S.A. Joosse, K. Pantel, Cancer Cell 28 (2015) 552–554.
[18]
X.M. Tang, T.T. Ye, X.J. You, et al., Chin. Chem. Lett. 34 (2023) 107531.
[19]
W.B. Tao, N. Bin Xie, Q.Y. Cheng, et al., Chin. Chem. Lett. 34 (2023) 108243.
[20]
A. Amalric, A. Bastide, A. Attina, et al., Crit. Rev. Clin. Lab. Sci. 59 (2022) 1–18.
[21]
C. Qi, H. Jiang, J. Xiong, et al., Chin. Chem. Lett. 30 (2019) 553–557.
[22]
M.Y. Chen, Z. Gui, K.K. Chen, et al., Chin. Chem. Lett. 33 (2022) 2086–2090.
[23]
A. Kupsco, G. Gonzalez, B.H. Baker, et al., Environ. Int. 144 (2020) 106021.
[24]
J. Xie, Z. Huang, P. Jiang, et al., Front. Immunol. 12 (2021) 1–11.
[25]
H. Yin, Z. Huang, S. Niu, et al., Front. Immunol. 13 (2022) 1–16.
[26]
L. Zhang, Y. Li, J. Wang, et al., Hypertension 79 (2022) E67–E69.
[27]
W. Huang, C.B. Qi, S.W. Lv, et al., Anal. Chem. 88 (2016) 1378–1384.
[28]
L. Cui, R. Ma, J. Cai, et al., Signal Transduct. Target. Ther. 7 (2022) 334.
[29]
D. Han, M.M. Xu, Annu. Rev. Immunol. 41 (2023) 73–98.
[30]
Y. Kong, J. Yu, S. Ge, et al., Innovation 4 (2023) 100452.
[31]
N.B.Y. Tsui, E.K.O. Ng, Y.M.D. Lo, Clin. Chem. 48 (2002) 1647–1653.
[32]
L. Li, W. Miao, P. Williams, et al., J. Am. Chem. Soc. 141 (2019) 10958–10961.
[33]
C. Guo, Y. Hu, X. Cao, et al., Anal. Chem. 93 (2021) 17060–17068.
[34]
X. Zhang, Y. Hu, X. Hong, et al., J. Chromatogr. B 1209 (2022) 123428.
[35]
Y. Hu, X. Hong, Z. Yuan, et al., Chin. Chem. Lett. 34 (2023) 108023.
[36]
F. Richter, J.E. Plehn, L. Bessler, et al., Nucleic. Acids. Res. 50 (2022) 4201–4215.
[37]
Y. Wang, J. Wang, X. Li, et al., Nat. Commun. 12 (2021) 1–19.
[38]
M. Yan, Y. Wang, Y. Hu, et al., Anal. Chem. 85 (2013) 12173–12181.
[39]
M.Y. Chen, C.B. Qi, X.M. Tang, et al., Chin. Chem. Lett. 33 (2022) 3772–3776.
[40]
M.B. Amin, F.L. Greene, S.B. Edge, et al., CA. Cancer J. Clin. 67 (2017) 93–99.
[41]
X. Deng, Y. Qing, D. Horne, et al., Nat. Rev. Clin. Oncol. 20 (2023) 507–526.
[42]
X. Cao, Q. Geng, D. Fan, et al., Mol. Cancer. 22 (2023) 1–23.
[43]
H. Chen, Y. Pan, Q. Zhou, et al., Gastroenterology 163 (2022) 891–907.
[44]
X. He, L. Tan, J. Ni, et al., Cancer Gene Ther. 28 (2021) 188–196.
[45]
R. Karthiya, S.M. Wasil, P. Khandelia, Mol. Biol. Rep. 47 (2020) 9189–9199.
[46]
G. Jin, M. Xu, M. Zou, et al., Mol. Ther. - Nucleic Acids 20 (2020) 13–24.
[47]
X. Chen, Y. Hao, Y. Liu, et al., Adv. Sci. 10 (2023) 2302705.
[48]
K.D. Nance, S.T. Gamage, M.M. Alam, et al., Cell Chem. Biol. 29 (2022) 312–320 e7.
[49]
H. Song, J. Zhang, B. Liu, et al., Biomark. Res. 10 (2022) 1–15.
[50]
D.W. Leung, G.K. Amarasinghe, Curr. Opin. Struct. Biol. 36 (2016) 133–141.
[51]
P. Keller, I. Freund, V. Marchand, et al., Nucleic Acids Res. 46 (2018) 9764–9775.
[52]
K. Karikó, M. Buckstein, H. Ni, et al., Immunity 23 (2005) 165–175.
[53]
D.D. Chaplin, J. Allergy Clin. Immunol. 125 (2010) S3–S23.
Appendix
Less
Year 2025 volume 36 Issue 3
PDF
43
23
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.cclet.2024.110079
  • Receive Date：2024-01-23
  • Online Date：2025-11-07
  • Published：2025-03-15
Article Data
Affiliations
History
  • Received：2024-01-23
  • Revised：2024-04-15
  • Accepted：2024-05-31
Affiliations
    a Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
    b Department of Chemistry, Zhejiang University, Hangzhou 310058, China
    c Cancer Center, Zhejiang University, Hangzhou 310058, China
    d Department of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
    e Analysis Center of Agrobiology and Environmental Sciences, Zhejiang University, Hangzhou 310058, China
References
Share
https://castjournals.cast.org.cn/joweb/ccl/EN/10.1016/j.cclet.2024.110079
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House